Scholarlink

Objective <p>To investigate the current adherence status and influencing factors for acute and preventive pharmacotherapy among migraine patients in China.</p> Methods <p>Utilizing a prospective cohort design with retrospective identification, migraine patients first attending the Headache Clinic (Chinese PLA General Hospital, May–November 2024) were prospectively assessed for treatment adherence and influencing factors via structured telephone follow-ups.</p> Results <p>Among 456 enrolled patients (75.9% female, 24.1% male), migraine subtypes included probable migraine (14.9%), migraine without aura (72.6%), migraine with aura (4.2%), and chronic migraine (8.3%). Good adherence rates were 30.5% for acute and 53.3% for preventive pharmacotherapy. Key non-adherence behaviors for acute medication: Abstinence from medication during attacks (63.1%) and administration after pain progression to moderate/severe intensity (35.0%). Primary reasons: mild headache deemed non-requiring medication (43.3%) and fear of potential adverse effects (36.0%). Key non-adherence behaviors for preventive medication: incomplete treatment course duration (76.4%), failure to obtain prescribed medications (15.3%), and non-adherence to prescribed medication schedule (11.1%). Primary reasons given for nonadherence to preventive medication included perceived prescription inappropriateness (43.1%) and adverse effects that occurred (19.4%). Multivariate regression analysis revealed that adherence to acute pharmacotherapy increased with higher educational level, medical insurance coverage, satisfaction with pain relief, and enhanced patient valuation of pharmacotherapy (all <i>p</i> &lt; 0.05). For preventive medication, adherence was associated with adverse effects, satisfaction with treatment efficacy, and enhanced patient valuation of pharmacotherapy (all <i>p</i> &lt; 0.05). Good adherence independently predicted fewer monthly headache days (MHD: 3.4 ± 3.9 days vs. 7.7 ± 6.1 days, <i>p</i> &lt; 0.01).</p> Conclusion <p>Suboptimal medication adherence persists among Chinese migraine patients, with patient valuation of pharmacotherapy being the strongest modifiable factor. Interventions should prioritize patient education, personalized treatment plans, and tailored adherence strategies to improve outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adherence status and influencing factors of acute and preventive pharmacotherapy among migraine patients in China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月9日

查看全文
  • Cancan Chen,
  • Zizi He,
  • Jing Zhang,
  • Longteng Ma,
  • Li Kang,
  • Hui Su,
  • Zhenjie Ma,
  • Shuqing Wang,
  • Yunyun Huo,
  • Shengyuan Yu,
  • Ye Ran,
  • Zhao Dong

摘要

Objective

To investigate the current adherence status and influencing factors for acute and preventive pharmacotherapy among migraine patients in China.

Methods

Utilizing a prospective cohort design with retrospective identification, migraine patients first attending the Headache Clinic (Chinese PLA General Hospital, May–November 2024) were prospectively assessed for treatment adherence and influencing factors via structured telephone follow-ups.

Results

Among 456 enrolled patients (75.9% female, 24.1% male), migraine subtypes included probable migraine (14.9%), migraine without aura (72.6%), migraine with aura (4.2%), and chronic migraine (8.3%). Good adherence rates were 30.5% for acute and 53.3% for preventive pharmacotherapy. Key non-adherence behaviors for acute medication: Abstinence from medication during attacks (63.1%) and administration after pain progression to moderate/severe intensity (35.0%). Primary reasons: mild headache deemed non-requiring medication (43.3%) and fear of potential adverse effects (36.0%). Key non-adherence behaviors for preventive medication: incomplete treatment course duration (76.4%), failure to obtain prescribed medications (15.3%), and non-adherence to prescribed medication schedule (11.1%). Primary reasons given for nonadherence to preventive medication included perceived prescription inappropriateness (43.1%) and adverse effects that occurred (19.4%). Multivariate regression analysis revealed that adherence to acute pharmacotherapy increased with higher educational level, medical insurance coverage, satisfaction with pain relief, and enhanced patient valuation of pharmacotherapy (all p < 0.05). For preventive medication, adherence was associated with adverse effects, satisfaction with treatment efficacy, and enhanced patient valuation of pharmacotherapy (all p < 0.05). Good adherence independently predicted fewer monthly headache days (MHD: 3.4 ± 3.9 days vs. 7.7 ± 6.1 days, p < 0.01).

Conclusion

Suboptimal medication adherence persists among Chinese migraine patients, with patient valuation of pharmacotherapy being the strongest modifiable factor. Interventions should prioritize patient education, personalized treatment plans, and tailored adherence strategies to improve outcomes.